

CITATION REPORT

List of articles citing

Cardiovascular risk in systemic lupus erythematosus--evidence of increased oxidative stress and dyslipidaemia

DOI: 10.1093/rheumatology/keg212
British Journal of Rheumatology, 2003, 42, 758-62.

Source: <https://exaly.com/paper-pdf/35690685/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
71	Oral health, atherosclerosis, and cardiovascular disease. <i>Critical Reviews in Oral Biology and Medicine</i> , 2004 , 15, 403-13		256
70	Dyslipoproteinemia and premature atherosclerosis in pediatric systemic lupus erythematosus. <i>Current Rheumatology Reports</i> , 2004 , 6, 425-33	4.9	23
69	Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. <i>Arthritis and Rheumatism</i> , 2004 , 50, 3947-57		246
68	Cardiovascular disease in lupus patients: should all patients be treated with statins and aspirin?. <i>Best Practice and Research in Clinical Rheumatology</i> , 2005 , 19, 823-38	5.3	48
67	Not only...but also T factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. <i>Rheumatology</i> , 2005 , 44, 1492-502	3.9	217
66	High sensitivity C-reactive protein in systemic lupus erythematosus: relation to disease activity, clinical presentation and implications for cardiovascular risk. <i>Lupus</i> , 2005 , 14, 576-82	2.6	66
65	Activation of transforming growth factor-beta1 and early atherosclerosis in systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2006 , 8, R81	5.7	26
64	Premature atherosclerotic disease in systemic lupus erythematosus--role of inflammatory mechanisms. <i>Autoimmunity Reviews</i> , 2006 , 5, 101-5	13.6	66
63	The complex nature of the interaction between disease activity and therapy on the lipid profile in patients with pediatric systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2006 , 54, 1283-90		19
62	Prevalence of conventional and lupus-specific risk factors for cardiovascular disease in patients with systemic lupus erythematosus: A case-control study. <i>Arthritis and Rheumatism</i> , 2006 , 55, 892-9		81
61	Parameters of oxidative stress status in healthy subjects: their correlations and stability after sample collection. <i>Journal of Clinical Laboratory Analysis</i> , 2006 , 20, 139-48	3	21
60	Mycophenolate Mofetil: An Overview. <i>Lupus</i> , 2006 , 15, 70-77	2.6	3
59	Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles. <i>Expert Opinion on Biological Therapy</i> , 2007 , 7, 53-72	5.4	81
58	C-reactive protein and cognitive deficits in systemic lupus erythematosus. <i>Cognitive and Behavioral Neurology</i> , 2007 , 20, 31-7	1.6	22
57	Oxidative stress in systemic lupus erythematosus: relationship to disease activity and symptoms. <i>Lupus</i> , 2007 , 16, 195-200	2.6	66
56	Serum protein oxidation and apolipoprotein CIII levels in people with systemic lupus erythematosus with and without nephritis. <i>Free Radical Research</i> , 2007 , 41, 1301-12	4	30
55	Neuropsychological impairment in systemic lupus erythematosus: a comparison with multiple sclerosis. <i>Neuropsychology Review</i> , 2008 , 18, 149-66	7.7	44

54	Catalase -262C>T polymorphism in systemic lupus erythematosus in Poland. <i>Rheumatology International</i> , 2008 , 28, 1035-9	3.6	14
53	Manganese superoxide dismutase Ala-9Val mitochondrial targeting sequence polymorphism in systemic lupus erythematosus in Poland. <i>Clinical Rheumatology</i> , 2008 , 27, 827-31	3.9	12
52	High-sensitivity C-reactive protein: discriminator between patients with primary and secondary antiphospholipid syndrome. <i>Clinical Biochemistry</i> , 2008 , 41, 1449-53	3.5	6
51	Skin autofluorescence is increased in systemic lupus erythematosus but is not reflected by elevated plasma levels of advanced glycation endproducts. <i>Rheumatology</i> , 2008 , 47, 1554-8	3.9	41
50	Effects of inflammation on cholesterol metabolism: impact on systemic lupus erythematosus. <i>Current Rheumatology Reports</i> , 2009 , 11, 255-60	4.9	19
49	Evidence for chronically elevated serum protein oxidation in systemic lupus erythematosus patients. <i>Free Radical Research</i> , 2009 , 43, 117-27	4	38
48	Lupus registries: evolution and challenges. <i>Seminars in Arthritis and Rheumatism</i> , 2010 , 39, 224-45	5.3	16
47	Antibodies to apolipoprotein A-I, high-density lipoprotein, and C-reactive protein are associated with disease activity in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2010 , 62, 845-54		88
46	Markers of oxidative and nitrosative stress in systemic lupus erythematosus: correlation with disease activity. <i>Arthritis and Rheumatism</i> , 2010 , 62, 2064-72		115
45	Oxidative protein damage and antioxidant status in systemic lupus erythematosus. <i>Clinical and Experimental Dermatology</i> , 2010 , 35, 287-94	1.8	31
44	Detection of serum beta(2)-GPI-Lp(a) complexes in patients with systemic lupus erythematosus. <i>Clinica Chimica Acta</i> , 2010 , 411, 395-9	6.2	11
43	Association of systemic lupus erythematosus with low serum bilirubin levels. <i>Scandinavian Journal of Rheumatology</i> , 2010 , 39, 480-4	1.9	27
42	Inflammatory biomarkers and oxidative stress measurements in patients with systemic lupus erythematosus with or without metabolic syndrome. <i>Lupus</i> , 2011 , 20, 1356-64	2.6	28
41	Protecting the kidneys in lupus nephritis. <i>International Journal of Clinical Rheumatology</i> , 2011 , 6, 529-546.5	6.5	10
40	Oxidative stress is associated with liver damage, inflammatory status, and corticosteroid therapy in patients with systemic lupus erythematosus. <i>Lupus</i> , 2011 , 20, 1250-9	2.6	45
39	Association of catalase gene polymorphisms with catalase activity and susceptibility to systemic lupus erythematosus in the Suez Canal area, Egypt. <i>Lupus</i> , 2012 , 21, 1244-9	2.6	14
38	Cardiovascular risk in autoimmune disorders: role of asymmetric dimethylarginine. <i>European Journal of Pharmacology</i> , 2012 , 696, 5-11	5.3	14
37	Metabolic disturbances associated with systemic lupus erythematosus. <i>PLoS ONE</i> , 2012 , 7, e37210	3.7	126

36	Mechanisms of Tissue DamageFree Radicals and Fibrosis. 2013 , 175-189		
35	Aortic Atherosclerosis in Systemic Lupus Erythematosus. <i>Rheumatology (Sunnyvale, Calif)</i> , 2014 , Suppl 5,		3
34	[Atherosclerosis in systemic lupus erythematosus]. <i>Presse Medicale</i> , 2014 , 43, 1034-47	2.2	9
33	Accelerated vascular disease in systemic lupus erythematosus: role of macrophage. <i>Clinical Immunology</i> , 2015 , 157, 133-44	9	15
32	Lipid peroxidation as risk factor for endothelial dysfunction in antiphospholipid syndrome patients. <i>Clinical Rheumatology</i> , 2016 , 35, 2485-93	3.9	9
31	High-density lipoprotein antioxidant capacity, subpopulation distribution and paraoxonase-1 activity in patients with systemic lupus erythematosus. <i>Lipids in Health and Disease</i> , 2016 , 15, 60	4.4	35
30	Lycopene reduces mortality in people with systemic lupus erythematosus: A pilot study based on the third national health and nutrition examination survey. <i>Journal of Dermatological Treatment</i> , 2016 , 27, 430-5	2.8	6
29	Metabolic profiling reveals new serum biomarkers of lupus nephritis. <i>Lupus</i> , 2017 , 26, 1166-1173	2.6	14
28	Clinical significance of lipid profile in systemic lupus erythematosus patients: Relation to disease activity and therapeutic potential of drugs. <i>Egyptian Rheumatologist</i> , 2017 , 39, 93-98	1	7
27	Arterial stiffness and peripheral arterial disease in patients with systemic lupus erythematosus. <i>Rheumatology International</i> , 2017 , 37, 293-298	3.6	14
26	Potential Role of Cytochrome c and Tryptase in Psoriasis and Psoriatic Arthritis Pathogenesis: Focus on Resistance to Apoptosis and Oxidative Stress. <i>Frontiers in Immunology</i> , 2018 , 9, 2363	8.4	28
25	Effects of 12-week Aerobic Exercise on Arterial Stiffness, Inflammation, and Cardiorespiratory Fitness in Women with Systemic LUPUS Erythematosus: Non-Randomized Controlled Trial. <i>Journal of Clinical Medicine</i> , 2018 , 7,	5.1	18
24	Systemic Inflammatory Response and Atherosclerosis: The Paradigm of Chronic Inflammatory Rheumatic Diseases. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	72
23	Systemic Lupus Erythematosus and Increased Prevalence of Atherosclerotic Cardiovascular Disease in Hospitalized Patients. <i>Mayo Clinic Proceedings</i> , 2019 , 94, 1436-1443	6.4	13
22	Exercise therapy in patients with idiopathic inflammatory myopathies and systemic lupus erythematosus - A systematic literature review. <i>Best Practice and Research in Clinical Rheumatology</i> , 2020 , 34, 101547	5.3	11
21	LOX-1: A potential driver of cardiovascular risk in SLE patients. <i>PLoS ONE</i> , 2020 , 15, e0229184	3.7	12
20	Atherosclerotic Cardiovascular Disease Prevalence Among Patients With Celiac Disease in the United States: An Observational Study. <i>Mayo Clinic Proceedings</i> , 2021 , 96, 666-676	6.4	1
19	Understanding Accelerated Atherosclerosis in Systemic Lupus Erythematosus: Toward Better Treatment and Prevention. <i>Inflammation</i> , 2021 , 44, 1663-1682	5.1	6

18	Serum Metabolomic Signatures Can Predict Subclinical Atherosclerosis in Patients With Systemic Lupus Erythematosus. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021 , 41, 1446-1458	9.4	6
17	Autoimmune Rheumatic Diseases: An Update on the Role of Atherogenic Electronegative LDL and Potential Therapeutic Strategies. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	1
16	QRISK3 Relation to Carotid Plaque is Higher than that of SCORE In Patients with Systemic Lupus Erythematosus. <i>Rheumatology</i> , 2021 ,	3.9	1
15	Pharmacological management of cardiovascular risk in chronic inflammatory rheumatic diseases. <i>Expert Review of Clinical Pharmacology</i> , 2020 , 13, 605-613	3.8	2
14	Dyslipidaemia in rheumatological autoimmune diseases. <i>Open Cardiovascular Medicine Journal</i> , 2011 , 5, 64-75	0.7	59
13	Oxidative stress and human health. <i>Advances in Bioscience and Biotechnology (Print)</i> , 2012 , 03, 997-1019	0.9	200
12	Cardiac involvement in systemic lupus erythematosus. <i>Annales Universitatis Mariae Curie-Sklodowska Sectio D: Medicina</i> , 2008 , 63, 25-31		
11	Metabolic Syndrome Post Liver Transplantation. 2015 , 218-229		
10	Lipid-lowering therapy in selected specific groups of patients. <i>Medicina Pro Praxi</i> , 2020 , 17, 151-156	0	
9	Using serum metabolomics analysis to predict sub-clinical atherosclerosis in patients with SLE.		0
8	The Role of Immunometabolism in the Pathogenesis of Systemic Lupus Erythematosus.. <i>Frontiers in Immunology</i> , 2021 , 12, 806560	8.4	0
7	Motivational interviewing intervention for increasing physical activity and improving dietary behaviors: The lupus intervention fatigue trial protocol.. <i>Contemporary Clinical Trials</i> , 2022 , 114, 106690	2.3	0
6	Sex Differences in Lipid Metabolism: Implications for Systemic Lupus Erythematosus and Cardiovascular Disease Risk. <i>Frontiers in Medicine</i> , 9,	4.9	1
5	2-Arachidonoylglycerol Reduces the Production of Interferon-Gamma in T Lymphocytes from Patients with Systemic Lupus Erythematosus. <i>Biomedicines</i> , 2022 , 10, 1675	4.8	
4	Labelfree mapping and profiling of altered lipid homeostasis in the rat hippocampus after traumatic stress: Role of oxidative homeostasis. 2022 , 20, 100476		
3	Effects of Hydroxychloroquine on markers of oxidative stress and antioxidant reserve in rheumatoid arthritis patients. 2022 , 12, 65-71		0
2	Immune mechanisms associated with cardiovascular disease in systemic lupus erythematosus: A path to potential biomarkers. 13,		0
1	Nutritional Approaches to Modulate Cardiovascular Disease Risk in Systemic Lupus Erythematosus: A Literature Review. 2023 , 15, 1036		1

